Downloads
Abstract
Purpose: To evaluate the treatment response of hepatocellular carcinoma (HCC) after transarterial
chemoembolization (TACE) using mRECIST.
Methods: Diagnosis of HCC was based on EASL 2018, and an indication of TACE was based on SIR
practice guideline. Treatment responses were evaluated at < 3 - month, 3 - 6 - month, 6 - 12 - month and
> 12 - month intervals.
Results: Forty - sixpatients (male/female 39/7) with the mean age 61.5 ± 11.2 years were enrolled in the
present study. The mean follow - up duration was 223 days (range, 42 - 723 days). The mean of maximal
HCC diameter was 62mm (range, 10 - 153mm). 23.9% of patients had portal vein thrombosis (PVT). The rates of complete response of the target lesions at the < 3 - month, 3 - 6 - month, 6 - 12 - month and >
12 - month were 33.3%; 33.3%; 35.3% and 33.3%, respectively. Progression disease was seen in 16.7%.
Infiltrative type, diameter > 10cm, bilobar HCC, and portal vein thrombosis were predictors for recurrence.
Conclusion: TACE offered short - term therapeutic control of HCC when using mRECIST
References
Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn
RS, Abecassis MM, et al. Diagnosis, Staging,
and Management of Hepatocellular Carcinoma:
Practice Guidance by the American
Association for the Study of Liver Diseases.
Hepatology. 2018. 68: 723-750.
Sieghart W, Hucke F, Peck - Radosavljevic M.
Transarterial chemoembolization: modalities,
indication, and patient selection. J Hepatol.
62: 1187-95.
EASL. EASL Clinical Practice Guidelines:
Management of hepatocellular carcinoma. J
Hepatol. 2018. 69: 182-236.
Llovet JM, Real MI, Montaña X, Planas R,
Coll S, Aponte J, et al. Arterial embolisation
or chemoembolisation versus symptomatic
treatment in patients with unresectable
hepatocellular carcinoma: a randomised
controlled trial. Lancet. 2002. 359: 1734-9.
Lencioni R, de Baere T, Soulen MC, Rilling
WS, Geschwind JF. Lipiodol transarterial
chemoembolization for hepatocellular
carcinoma: A systematic review of efficacy and
safety data. Hepatology. 2016. 64: 106-16.
Ichikawa T, Machida N, Sasaki H, Tenmoku A,
Kaneko H, Negishi R, et al. Early Prediction
of the Outcome Using Tumor Markers and
mRECIST in Unresectable Hepatocellular
Carcinoma Patients Who Underwent
Transarterial Chemoembolization. Oncology.
91: 317-330.
Gaba RC, Lokken RP, Hickey RM, Lipnik
AJ, Lewandowski RJ, Salem R, et al. Quality
Improvement Guidelines for Transarterial
Chemoembolization and Embolization of
Hepatic Malignancy. J Vasc Interv Radiol. 2017.
: 1210-1223 e3.
Llovet JM , Lencioni R. mRECIST for HCC:
Performance and novel refinements. J Hepatol.
72: 288-306.
Younes EH, Zahra HF, Soumaya BM, Maria L,
Nada L, Hakima A, et al. Study of predictive factors
of complete response after chemoembolization
for unresectable hepatocellular carcinoma in 162
patients. Clin Exp Hepatol. 2020. 6: 313-320.
Domaratius C, Settmacher U, Malessa C,
Teichgraber U. Transarterial chemoembolization
with drug - eluting beads in patients with
hepatocellular carcinoma: response analysis with
mRECIST. Diagn Interv Radiol. 2021. 27: 85-93. 11. Vesselle G., Quirier-Leleu C., Velasco S.,
Charier F., Silvain C., Boucebci S., et al.
Predictive factors for complete response of
chemoembolization with drug - eluting beads
(DEB-TACE) for hepatocellular carcinoma. Eur
Radiol. 2016. 26: 1640-1648.
Dioguardi Burgio M., Sartoris R., Libotean C.,
Zappa M., Sibert A., Vilgrain V., et al. Lipiodol
retention pattern after TACE for HCC is a predictor
for local progression in lesions with complete
response. Cancer Imaging. 2019. 19: 75.
Wang CY, Li S. Clinical characteristics and
prognosis of 2887 patients with hepatocellular
carcinoma: A single center 14 years experience
from China. Medicine (Baltimore). 2019. 98:
e14070.
Jiang JF, Lao YC, Yuan BH, Yin J, Liu X, Chen
L, et al. Treatment of hepatocellular carcinoma
with portal vein tumor thrombus: advances and
challenges. Oncotarget. 2017. 8: 33911-33921.
Cerrito L, Annicchiarico BE, Iezzi R, Gasbarrini
A, Pompili M, Ponziani FR. Treatment of
hepatocellular carcinoma in patients with portal
vein tumor thrombosis: Beyond the known
frontiers. World J Gastroenterol. 2019. 25:
-4382.
| Published | 03-12-2021 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 74 (2021) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.2021.74.6 | |
| Keywords | Ung thư biểu mô tế bào gan, nút mạch hóa chất, mRECIST Hepatocellular carcinoma, transarterial chemoembolization, mRECIST |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2021 Journal of Clinical Medicine Hue Central Hospital